Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid;Therapie schwerer akneiformer cetuximab-exantheme mit oralem retinoid, topischem antibiotikum und steroidexternum

Hautarzt

Volumn 58, Issue 7, 2007, Pages 615-618

  Wollenberg, A ^a,b   Moosmann, N ^b   Kroth, J ^a   Heinemann, V ^b   Klein, E ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Acneiform drug eruption; Cetuximab; EGFR inhibition; Retinoid

Indexed keywords

ANTIBIOTIC AGENT; CETUXIMAB; CORTICOSTEROID; IRINOTECAN; ISOTRETINOIN; NADIFLOXACIN; PREDNICARBATE; RETINOID;

ACNE; ADULT; ARTICLE; BODY SURFACE; CANCER CHEMOTHERAPY; CASE REPORT; CHEILITIS; COLORECTAL CARCINOMA; DISEASE SEVERITY; FACE; HUMAN; MALE; METASTASIS;

ACNEIFORM ERUPTIONS; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; QUINOLIZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 34447635661     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1256-y     Document Type: Article

References (12)

1. Busam KJ, Capodieci P, Motzer R et al. (2001) Cutaneous side-effects in cancer patients treated with antiepidermal growth factorreceptor antibody C225. Br J Dermatol 144: 1169-1176
2. Ciardiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 11: 755-768
3. Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
4. Fan Z, Masui H, Atlas I, Mendelsohn J (1993) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53: 4322-4328
5. Gutzmer R, Werfel T, Mao R et al. (2005) Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 153: 849-851
6. Gutzmer R, Werfel T, Kapp A, Elsner J (2006) Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt 57: 509-513
7. Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292-302
8. Murata K, Sugita K, Kobayashi M et al. (2006) Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. J Dermatol Sci 42: 91-99
9. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37 [Suppl 4]: 9-15
10. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208
11. Segaert S, Tabernero J, Chosidow O et al. (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3: 599-606
12. Shah NT, Kris MG, Pao W et al. (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23: 165-174